Altair L. Dube
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Altair L. Dube has a total of 27 co-authors. Here are the top co-authors by number of shared publications:
- Alberto Bremauntz Enriquez
University of Texas Southwestern Medical Center 1 Division of Endocrinology, Department of Internal Medicine Dallas, Texas
4 shared publications - Bruce A. Posner
University of Texas Southwestern Medical Center 2 Department of Biochemistry Dallas, Texas
4 shared publications - Cynthia J. Meyer
University of Texas Southwestern Medical Center 2 Department of Biochemistry Dallas, Texas
4 shared publications - Danielle Sherry
University of Texas Southwestern Medical Center 1 Division of Endocrinology, Department of Internal Medicine Dallas, Texas
4 shared publications - David G. McFadden
Department of Internal Medicine, Division of Endocrinology, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA
4 shared publications - Florentina Vandiver
University of Texas Southwestern Medical Center 1 Division of Endocrinology, Department of Internal Medicine Dallas, Texas
4 shared publications
Latest Publications
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Table S10 from CDK8 Inhibition Induces Mediator Trapping and Impairment of the EWSR1::FLI1 Transcriptional Program in Ewing Sarcoma
Supplementary Table S10 from CDK8 Inhibition Induces Mediator Trapping and Impairment of the EWSR1::FLI1 Transcriptional Program in Ewing Sarcoma
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Table S10 from CDK8 Inhibition Induces Mediator Trapping and Impairment of the EWSR1::FLI1 Transcriptional Program in Ewing Sarcoma
Supplementary Table S10 from CDK8 Inhibition Induces Mediator Trapping and Impairment of the EWSR1::FLI1 Transcriptional Program in Ewing Sarcoma
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Figures S1-S6 from CDK8 Inhibition Induces Mediator Trapping and Impairment of the EWSR1::FLI1 Transcriptional Program in Ewing Sarcoma
Supplementary Figures S1-S6 and their legends.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figures S1-S6 from CDK8 Inhibition Induces Mediator Trapping and Impairment of the EWSR1::FLI1 Transcriptional Program in Ewing Sarcoma
Supplementary Figures S1-S6 and their legends.
- Open Access
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Supplementary Tables S1-S9 from CDK8 Inhibition Induces Mediator Trapping and Impairment of the EWSR1::FLI1 Transcriptional Program in Ewing Sarcoma
S1 Differentially-expressed genes at 6-, 12-, or 24- hours (log2 >/= 1 at any time point) following EF depletion in A673 EF-SMASh cells treated with 312nM danoprevir. S2 HTS Primary Screen S3 HTS Validation Screen S4 HTS resupplied Compounds S5 Differentially expressed genes (log2 >0.58) after treatment with SW393109 or CCT251921; log2 >/= 1 for the comparator EF-depletion RNA sequencing S6 Enrichr analysis of the DEGs (log2 > 0.58) for the stated cell lines and conditions. S7 Pooled CRISPR Screening Gene-based log2 fold changes with depletion score S8 Log2 fold change in gene expression in AID-CDK8; CDK19 KO clones with 5-Ph-IAA, SW393109 or combination S9 IP-MS Proteomics Enrichment.
- 2 November 2026
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Tables S1-S9 from CDK8 Inhibition Induces Mediator Trapping and Impairment of the EWSR1::FLI1 Transcriptional Program in Ewing Sarcoma
S1 Differentially-expressed genes at 6-, 12-, or 24- hours (log2 >/= 1 at any time point) following EF depletion in A673 EF-SMASh cells treated with 312nM danoprevir. S2 HTS Primary Screen S3 HTS Validation Screen S4 HTS resupplied Compounds S5 Differentially expressed genes (log2 >0.58) after treatment with SW393109 or CCT251921; log2 >/= 1 for the comparator EF-depletion RNA sequencing S6 Enrichr analysis of the DEGs (log2 > 0.58) for the stated cell lines and conditions. S7 Pooled CRISPR Screening Gene-based log2 fold changes with depletion score S8 Log2 fold change in gene expression in AID-CDK8; CDK19 KO clones with 5-Ph-IAA, SW393109 or combination S9 IP-MS Proteomics Enrichment.
- 14 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (11) , 2366-2391
CDK8 Inhibition Induces Mediator Trapping and Impairment of the EWSR1::FLI1 Transcriptional Program in Ewing Sarcoma
Ewing sarcoma is characterized by a chromosomal translocation resulting in the fusion protein EWSR1::FLI1. We utilize endogenous EWSR1::FLI1 target gene reporters in patient-derived cell lines to perform a high-throughput phenotypic screen to identify small molecules that impair the EWSR1::FLI1 transcriptional program. We discovered that inhibitors of cyclin-dependent kinase 8 (CDK8), including a novel pyridyl imidazole, altered transcription of EWSR1::FLI1 target genes and CDK8 co-localized with EWSR1::FLI1 preferentially on single GGAA DNA-binding motifs. Using pooled CRISPR screening, biochemical studies, and chromatin profiling, we discovered that CDK8 inhibitors suppressed proliferation of Ewing sarcoma cells through a gain-of-function mechanism by inducing molecular trapping of the CDK8 kinase module and Mediator complex on chromatin. This mechanism has implications for the development of small molecules to target transcription and suggests that impairment of transcriptional regulatory complex dynamics might serve as a vulnerability in cancers in which the dominant oncogenes act as dosage-sensitive transcription factors. Significance: A high-throughput screen using endogenous EF target gene reporter alleles identified CDK8 as a modifier of EF transcriptional regulation. Using pooled CRISPR screening, biochemical studies, and chromatin profiling, we discovered that CDK8 inhibitors impaired transcriptional regulation through molecular trapping of CDK8 and the Mediator complex on chromatin. See related commentary by Stevens and Hatley, p. 2210
- 14 July 2026
- Published by American Association for Cancer Research (AACR) in Cancer Discovery
- Vol. 16 (11) , 2366-2391
CDK8 Inhibition Induces Mediator Trapping and Impairment of the EWSR1::FLI1 Transcriptional Program in Ewing Sarcoma
Ewing sarcoma is characterized by a chromosomal translocation resulting in the fusion protein EWSR1::FLI1. We utilize endogenous EWSR1::FLI1 target gene reporters in patient-derived cell lines to perform a high-throughput phenotypic screen to identify small molecules that impair the EWSR1::FLI1 transcriptional program. We discovered that inhibitors of cyclin-dependent kinase 8 (CDK8), including a novel pyridyl imidazole, altered transcription of EWSR1::FLI1 target genes and CDK8 co-localized with EWSR1::FLI1 preferentially on single GGAA DNA-binding motifs. Using pooled CRISPR screening, biochemical studies, and chromatin profiling, we discovered that CDK8 inhibitors suppressed proliferation of Ewing sarcoma cells through a gain-of-function mechanism by inducing molecular trapping of the CDK8 kinase module and Mediator complex on chromatin. This mechanism has implications for the development of small molecules to target transcription and suggests that impairment of transcriptional regulatory complex dynamics might serve as a vulnerability in cancers in which the dominant oncogenes act as dosage-sensitive transcription factors. Significance: A high-throughput screen using endogenous EF target gene reporter alleles identified CDK8 as a modifier of EF transcriptional regulation. Using pooled CRISPR screening, biochemical studies, and chromatin profiling, we discovered that CDK8 inhibitors impaired transcriptional regulation through molecular trapping of CDK8 and the Mediator complex on chromatin. See related commentary by Stevens and Hatley, p. 2210
- 7 August 2018
- Published by Springer Nature
- Vol. 65, 49-67
Starfish as a Model System for Analyzing Signal Transduction During Fertilization
The starfish oocyte and egg offer advantages for use as a model system for signal transduction research. Some of these have been recognized for over a century, including the ease of procuring gametes, in vitro fertilization, and culturing the embryos. New advances, particularly in genomics, have also opened up opportunities for the use of these animals. In this chapter, we give a few examples of the historical use of the starfish for research in cell biology and then describe some new areas in which we believe the starfish can contribute to our understanding of signal transduction—particularly in fertilization.
- 7 August 2018
- Published by Springer Nature
- Vol. 65, 49-67
Starfish as a Model System for Analyzing Signal Transduction During Fertilization
The starfish oocyte and egg offer advantages for use as a model system for signal transduction research. Some of these have been recognized for over a century, including the ease of procuring gametes, in vitro fertilization, and culturing the embryos. New advances, particularly in genomics, have also opened up opportunities for the use of these animals. In this chapter, we give a few examples of the historical use of the starfish for research in cell biology and then describe some new areas in which we believe the starfish can contribute to our understanding of signal transduction—particularly in fertilization.